HEALTH

Medical Breakthrough: Low-Cost Antidepressant Found to Combat Long COVID Fatigue

Researchers find that the low-cost antidepressant fluvoxamine significantly reduces fatigue in long COVID patients, offering a major breakthrough for millions.

Published

on

A Major Advance in Long COVID Treatment

A global research team co-led by McMaster University has announced a significant breakthrough in the treatment of long COVID, identifying one of the first medications proven to meaningfully reduce persistent fatigue. According to a randomized, placebo-controlled clinical trial published in the Annals of Internal Medicine, the widely available antidepressant fluvoxamine significantly improved both energy levels and the overall quality of life for patients struggling with the long-term effects of the virus.

Fatigue remains the most debilitating symptom for the estimated 65 million people living with long COVID worldwide. For many, the exhaustion is so profound that it prevents them from returning to work or engaging in daily family activities. Despite the scale of the crisis, medical guidelines have largely been limited to supportive care and pacing due to a lack of evidence-based pharmacological options.

The REVIVE-TOGETHER Trial Results

The study, known as the REVIVE-TOGETHER trial, involved 399 adults in Brazil who had experienced persistent fatigue for at least 90 days following a COVID-19 infection. Participants were randomly assigned to receive either fluvoxamine, the diabetes medication metformin, or a placebo for 60 days. The results were stark: researchers found a 99 percent probability that fluvoxamine outperformed the placebo in reducing fatigue. Conversely, while metformin has previously shown promise in preventing long COVID if taken during the initial infection, it offered no meaningful benefit for those with established fatigue symptoms.

“This is an important step forward for patients who have been desperate for evidence-based options,” said Edward Mills, senior author and professor at McMaster University. He noted that because fluvoxamine is already widely used and well-understood by the medical community, it has immediate potential for clinical application.

Innovation in Clinical Research

Beyond the discovery of the drug’s efficacy, the trial was notable for its sophisticated Bayesian adaptive design. This allowed the international team—comprising researchers from Stanford, UBC, Duke, and several Brazilian institutions—to reach conclusions more efficiently than traditional trials. The study was able to stop specific treatment arms once the evidence became clear, accelerating the delivery of much-needed data to the public.

While experts emphasize that long COVID is a complex condition that may require multiple treatment pathways, the identification of fluvoxamine provides clinicians with the first strong evidence for a medication that targets the condition’s most common symptom. Further research is expected to determine which specific patient profiles benefit most from the treatment.

Continue Reading

HEALTH

What You Need to Know About the Recent Surge in St. Stephen Overdose Calls

RCMP are investigating potential criminal links following a rise in drug overdose calls in St. Stephen, N.B., where multiple people were hospitalized.

Published

on

Emergency Responders Handle Spike in St. Stephen Overdose Incidents

Multiple individuals required hospitalization following a series of overdose calls in St. Stephen between Oct. 18 and Oct. 20. Non-profit organization Neighbourhood Works confirmed its shelter, Lighthouse Lodge, responded to an increased number of cases over the past week, with staff and emergency personnel providing urgent care before the patients were treated and released.

Police Search for Illicit Drug Suppliers

In response to the sudden rise in medical emergencies, the RCMP announced an investigation into possible criminal activity connected to the incidents. Mounties are actively seeking information regarding individuals who might be distributing illicit substances in the region. Although overdose responses are primarily medical, authorities are evaluating potential criminal ties.

Local Organization Warns of Unpredictable Drug Supply

Neighbourhood Works emphasized in a community letter that the specific substances involved remain unconfirmed pending official findings. The non-profit noted that these occurrences highlight the ongoing hazards of an unpredictable drug supply affecting both large centers and smaller rural areas like St. Stephen. The RCMP reminded the public that consuming illegal drugs carries inherent risks due to unknown contents, urging anyone with relevant information to contact local police or New Brunswick RCMP at 1-888-506-7267.

Continue Reading

COMMUNITY

Redeployment of Primary Care Nurse Practitioners to Emergency Rooms Raises Safety Concerns in Northern New Brunswick

Nurse practitioners in northern N.B. face forced redeployment to ER shifts at Campbellton Regional Hospital, raising patient care concerns.

Published

on

Staffing Shifts Trigger Patient Care Concerns

Patients in northern New Brunswick are facing potential disruptions to their health care as nurse practitioners are involuntarily reassigned from primary care positions to cover staffing shortages in a regional emergency room.

According to an Oct. 18 statement from Nurse Practitioners of New Brunswick, several employees from the Restigouche region—specifically around three to four practitioners residing in the Dalhousie area—have been reassigned to serve as registered nurses in the Campbellton Regional Hospital’s emergency department.

Concerns Over Legal and Professional Obligations

Sharon Hamilton, president of Nurse Practitioners of New Brunswick, cautioned that the sudden transfers place both patients and practitioners in jeopardy. She noted that affected practitioners received short notice—sometimes only days—before being assigned to hospital shifts expected to last up to six months.

“It puts the patients in great jeopardy,” Hamilton said, “as well as putting the nurse practitioner … their licence in jeopardy because they have a legal obligation to their patients.”

Hamilton stressed that nurse practitioners possess advanced training allowing them to prescribe medication, order tests, and diagnose conditions independently. Abrupt reassignments leave little time to arrange ongoing coverage, leaving practitioners concerned about legal responsibility if their regular primary care patients suffer delayed treatment or misdiagnosis. She warned that displaced patients might ultimately seek care at overcrowded emergency rooms.

Health Network Defends Necessary Emergency Coverage

Vitalité Health Network stated that the temporary involuntary reassignments are essential for keeping emergency services operational while new staff undergo training. Dr. France Desrosiers, CEO of the health network, explained via email that volunteers from other departments and health zones have assisted in Campbellton since the summer, but temporary forced redeployments remain necessary for a small number of workers.

“These measures are necessary to navigate this transition period and maintain access to essential services,” Desrosiers wrote, adding that while open to finding long-term solutions, the network will not halt reassignments until an alternative is established. “This is not about choosing between primary care and emergency services. Our responsibility is to protect both,” she stated.

Calls for Transparency and Long-Term Solutions

The advocacy group fears this temporary measure could establish a precedent permitting regional health authorities across the province to pull healthcare professionals from primary practices at will. Hamilton pointed out that taking providers out of primary care runs counter to provincial efforts to reduce the estimated 270,000 to 280,000 residents currently without a primary care provider.

Nurse Practitioners of New Brunswick is demanding transparency from Vitalité and the provincial government regarding the decision’s rationale and its full impact on local primary care. The organization is asking for timely replacement coverage for affected patients and urging officials to directly involve nurse practitioners in crafting a sustainable, long-term staffing strategy. The Department of Health did not respond to requests for comment.

Continue Reading

COMMUNITY

Free COVID-19, Flu, and RSV Vaccines Arrive for New Brunswick Residents This Fall

Free updated COVID-19, flu, and RSV vaccines will be available to eligible New Brunswick residents starting Oct. 13 through pharmacies and health clinics.

Published

on

Updated Immunization Access Starts Oct. 13

Free updated vaccinations against influenza and COVID-19 will become accessible to New Brunswick residents aged six months and older beginning Oct. 13. Individuals seeking to protect themselves can arrange appointments using the provincial web portal, through participating local pharmacies, or via select primary care providers. Both shots are permitted to be given during a single appointment.

Target Groups and Pediatric Delivery

Dr. Yves Léger, the province’s chief medical officer of health, strongly advises those facing higher risks of severe illness—including seniors aged 65 and up, residents of long-term care or congregate living facilities, expectant mothers, and individuals managing chronic medical conditions—to get immunized.

“With respiratory illness season approaching, vaccination is an important step people can take to protect their health and help protect others,” Dr. Léger stated. “Receiving both the flu and COVID-19 vaccines can reduce the chance of becoming seriously ill, requiring hospitalization and spreading illness to others.”

For children, shots can be accessed via Public Health offices or primary care providers, while select pharmacies cater to youth two years and older. Needle-hesitant youth between two and 17 years old can alternatively receive FluMist, an inhaled nasal spray flu vaccine.

RSV and Pneumococcal Disease Protection

The province’s 2026-27 respiratory illness prevention initiative also incorporates free coverage for respiratory syncytial virus (RSV) protection aimed at vulnerable groups, including seniors, infants, and individuals with compromised immune systems or conditions like diabetes and heart disease. RSV cases across New Brunswick dropped to 1,509 confirmed instances between August 2025 and August 2026, down from 2,552 recorded in the prior 12-month span.

Under the plan, infants born on or after April 1, 2026, can receive a single protective RSV dose prior to hospital discharge or via Public Health units, primary care providers, and First Nations community health centers before reaching eight months of age during their initial season. High-risk infants may qualify for a secondary dose in their second season.

Additionally, health officials urge residents 65 and older, as well as younger adults facing elevated risk, to verify their status regarding the free pneumococcal vaccine to guard against severe conditions such as pneumonia, bloodstream infections, and meningitis.

Continue Reading

Trending